Market Snapshot
S&P Futures
4,276.75
Dow Futures
33,884
Nasdaq Futures
13,514.5
Revelation Biosciences, Inc. (REVB) stock declined over -0.42% intraday to trade at $0.4767 a share on NASDAQ. The stock opened with a loss of -4.47% at $0.485 and touched an intraday high of $0.49, rising 1.21% against the last close of $0.471. The stock went to a low of $0.465 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-08-17 | $0.485 | $0.49 | $0.465 | $0.479 | 863,670 |
2022-08-16 | $0.499 | $0.5 | $0.462 | $0.471 | 1,121,700 |
2022-08-15 | $0.509 | $0.509 | $0.488 | $0.5 | 1,273,700 |
2022-08-12 | $0.51 | $0.519 | $0.49 | $0.502 | 813,000 |
2022-08-11 | $0.52 | $0.57 | $0.5 | $0.52 | 2,106,600 |
2022-08-10 | $0.544 | $0.55 | $0.505 | $0.518 | 1,228,900 |
2022-08-09 | $0.487 | $0.629 | $0.475 | $0.553 | 7,448,300 |
2022-08-08 | $0.51 | $0.511 | $0.482 | $0.495 | 1,110,200 |
2022-08-05 | $0.52 | $0.52 | $0.5 | $0.506 | 951,900 |
2022-08-04 | $0.513 | $0.534 | $0.492 | $0.509 | 1,429,900 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination. Revelation Biosciences, Inc. was founded in 2019 and is headquartered in San Diego, California.
Revelation Biosciences, Inc. (NASDAQ: REVB) stock price is $0.4767 as of the last check on Wednesday, August 17. During the trading session, REVB stock reached the peak price of $0.49 while $0.465 was the lowest point it dropped to.
The NASDAQ listed REVB is part of Biotechnology industry that operates in the broader Health Care sector. Revelation Biosciences, Inc. , a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics.
Mr. James M. Rolke
CEO & Director
Mr. Chester Stanley Zygmont III
Chief Financial Officer
Ms. Sandra Vedrick
VP of HR & Investor Relations
Ms. Carol Odle
Sr. Director of Clinical Projects
REVB stock traded closed the last session at $0.479, which is -$0.0020000000000000018 or -0.41779820346772545% lower than its previous close of $0.471. REVB's current trading price is 18.61% lower than its 52-week high of $11.29 where as its distance from 52-week low of 0.4% is -95.76%.
Number of REVB employees currently stands at -. REVB operates from 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122, United States.
Official Webiste of $REVB is: https://www.revbiosciences.com
REVB could be contacted at REVB operates from 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122, United States, or at phone #650-800-3717 and can also be accessed through its website.
REVB stock volume for the day was 214,518 shares while in the previous session number of REVB shares traded was 863,670 . The average number of REVB shares traded daily for last 3 months was 5.13 Million.
The percentage change in REVB stock occurred in the recent session was -0.41779820346772545% while the dollar amount for the price change in REVB stock was -$0.0020000000000000018.
In the recent session, the day high for REVB stock was $0.49 while the low for REVB stock touched on the day was $0.465.
The market value of REVB currently stands at 7.44 Million with its latest stock price at $0.4767 and 14.2 Million of its shares outstanding.